cailynn johnson
2 posts
Oct 22, 2024
11:13 PM
|
Since the CAR-T cell therapy may cause some acute on-target/on-tumor toxicity (cytokine release syndrome, tumor lysis syndrome) or on-target/off-tumor toxicity, and in some cases, CAR-T cells undergo antigen-independent proliferation that could increase cell-mediated toxicity and raise the concern of immortalization of infused CAR-T cells, evaluation of the cytotoxicity of the CAR-T cells and the possible adverse effects is the most important validation step for the safety consideration.
|
